BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35154270)

  • 1. RNA-Binding Protein IGF2BP1 Associated With Prognosis and Immunotherapy Response in Lung Adenocarcinoma.
    Liu J; Li Z; Cheang I; Li J; Zhou C
    Front Genet; 2022; 13():777399. PubMed ID: 35154270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. m
    Wu H; Xu H; Huang S; Tang Y; Tang J; Zhou H; Xie L; Qiao G
    Front Oncol; 2022; 12():989817. PubMed ID: 36249006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated Heterogeneous Nuclear Ribonucleoprotein C Expression Correlates With Poor Prognosis in Patients With Surgically Resected Lung Adenocarcinoma.
    Guo W; Huai Q; Zhang G; Guo L; Song P; Xue X; Tan F; Xue Q; Gao S; He J
    Front Oncol; 2020; 10():598437. PubMed ID: 33569346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comprehensive Analysis of the Relationship between m6A Methylation Patterns and Immune Microenvironment in Lung Adenocarcinoma].
    Ke J; Cui J; Yang X; Du X; Ma B; Yu L
    Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):311-322. PubMed ID: 35599007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ECE2 is a prognostic biomarker associated with m6A modification and involved in immune infiltration of lung adenocarcinoma.
    Zhang YH; Zeng J; Liu XS; Gao Y; Kui XY; Liu XY; Zhang Y; Pei ZJ
    Front Endocrinol (Lausanne); 2022; 13():1013238. PubMed ID: 36299451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of pathology-specific regulators of m
    Li N; Zhan X
    EPMA J; 2020 Sep; 11(3):485-504. PubMed ID: 32849929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Impact of
    Guo W; Huai Q; Wan H; Guo L; Song P; Gao S; He J
    DNA Cell Biol; 2021 Feb; 40(2):316-331. PubMed ID: 33493403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value and multiomic features of m6A-related risk signature in lung adenocarcinoma.
    Wang X; Yu Q; Yu H; Wang Y; Sun L; Yu L; Cui H; Yang H
    Am J Transl Res; 2022; 14(8):5379-5393. PubMed ID: 36105012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of Gene Signatures of m6ARNA Methylation Regulators in Lung Adenocarcinoma and Development of a Risk Scoring System.
    Gao C; Li H; Ma W; Zhang Q; Liu C; Liu L; Zhuang J; Sun C
    J Immunol Res; 2022; 2022():7519838. PubMed ID: 36061307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Ma Y; Yang J; Ji T; Wen F
    Front Genet; 2022; 13():990623. PubMed ID: 36246622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer/testis antigen HEMGN correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma.
    Jiang Y; Yu L; Hu Q; Kang Y; You J; Huang C; Xu X; Chen L
    Mol Immunol; 2023 Jan; 153():226-237. PubMed ID: 36563642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of N6-Methyladenosine Regulators on LAG3 and Immune Infiltrates in Lung Adenocarcinoma.
    Wang N; Xu Y; Jin L; Wang X; Wu S; Wang Y; Zhao J; Zhou F; Ge H
    Dis Markers; 2022; 2022():1829528. PubMed ID: 36051357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of prognostic genes in the tumor microenvironment of lung adenocarcinoma.
    Xu ZY; Zhao M; Chen W; Li K; Qin F; Xiang WW; Sun Y; Wei J; Yuan LQ; Li SK; Lin SH
    PeerJ; 2020; 8():e9530. PubMed ID: 32775050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An N6-Methyladenosine-Related Gene Set Variation Score as a Prognostic Tool for Lung Adenocarcinoma.
    Zhang H; Hu J; Liu A; Qu H; Jiang F; Wang C; Mo S; Sun P
    Front Cell Dev Biol; 2021; 9():651575. PubMed ID: 34307344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
    Wang W; Ren S; Wang Z; Zhang C; Huang J
    Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
    Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
    Front Immunol; 2021; 12():724741. PubMed ID: 34335635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant expression of m
    Kuai D; Zhu S; Shi H; Yang R; Liu T; Liu H; Min L; Zhang S
    Life Sci; 2021 May; 273():119258. PubMed ID: 33636176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.